Moleculin Biotech (NASDAQ:MBRX) Announces Earnings Results, Beats Expectations By $0.15 EPS

Moleculin Biotech (NASDAQ:MBRX – Get Free Report) released its quarterly earnings data on Thursday. The company reported ($1.40) EPS for the quarter, beating the consensus estimate of ($1.55) by $0.15, FiscalAI reports.

Moleculin Biotech Stock Up 6.8%

MBRX stock opened at $0.61 on Friday. Moleculin Biotech has a twelve month low of $0.16 and a twelve month high of $17.23. The stock has a market capitalization of $4.33 million, a price-to-earnings ratio of -0.03 and a beta of 1.83. The firm’s fifty day simple moving average is $2.03 and its two-hundred day simple moving average is $2.50.

Get Moleculin Biotech alerts:

Hedge Funds Weigh In On Moleculin Biotech

An institutional investor recently bought a new position in Moleculin Biotech stock. Jane Street Group LLC purchased a new stake in shares of Moleculin Biotech, Inc. (NASDAQ:MBRX – Free Report) during the 4th quarter, according to its most recent filing with the SEC. The institutional investor purchased 22,550 shares of the company’s stock, valued at approximately $75,000. Jane Street Group LLC owned about 1.11% of Moleculin Biotech at the end of the most recent quarter. 15.52% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on MBRX shares. Wall Street Zen raised shares of Moleculin Biotech from a “strong sell” rating to a “sell” rating in a report on Saturday. Weiss Ratings reissued a “sell (e+)” rating on shares of Moleculin Biotech in a research note on Friday, July 17th. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Moleculin Biotech has an average rating of “Hold” and an average target price of $22.00.

Get Our Latest Report on Moleculin Biotech

Moleculin Biotech Company Profile

(Get Free Report)

Moleculin Biotech, Inc is a clinical-stage pharmaceutical company focused on the development of novel therapies for the treatment of highly resistant tumors and viral infections. The company’s research platform centers on the design and synthesis of drug candidates that target key cellular pathways in cancer cells and viral replication processes. By leveraging a proprietary chemistry approach, Moleculin aims to address diseases that have limited therapeutic options and high unmet medical need.

The company’s pipeline includes multiple product candidates at various stages of development.

Featured Stories

• Five stocks we like better than Moleculin Biotech
• Texas Roadhouse and Brinker International Have the Recipe Rivals Are Missing
• AirJoule Technologies: Short Squeeze Setup Amid Rising Risks
• MarketBeat Week in Review – 08/10 – 08/14
• Sony and TSMC’s $4.7 Billion Venture Is About More Than Camera Sensors

Receive News & Ratings for Moleculin Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moleculin Biotech and related companies with MarketBeat.com's FREE daily email newsletter.